A Study of SGN-B6A in Chinese Participants With Advanced Solid Tumors
← catalyst calendarSponsored by Seagen, a wholly owned subsidiary of Pfizer (industry) · PFE — their whole pipeline →.
Phase
Phase 1
Status
Completed
Study type
Interventional
Design
Na · None · Treatment
Enrollment
6actual
Sites
3
Country
China
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2024-08-21 | actual | When the study began enrolling |
| Primary completion | 2025-11-18 | actual | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2025-11-18 | actual | The whole study's end, after follow-up |
| First posted | 2024-08-12 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2025-12-15 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Conditions
- Carcinoma, Non-Small Cell Lung
- Squamous Cell Carcinoma of Head and Neck
- Esophageal Squamous Cell Carcinoma
- Gastric Adenocarcinoma
- Esophageal Adenocarcinoma
- Gastroesophageal Junction Adenocarcinoma
Intervention
- Drug: sigvotatug vedotin
Primary outcomes
what the primary-completion date above is the date OFNumber of participants with adverse events (AEs)
measured Through 30-37 days following last dose of sigvotatug vedotin; up to 3 years
Number of participants with laboratory abnormalities
measured Through 30-37 days following last dose of sigvotatug vedotin; up to 3 years
Number of participants with dose-limiting toxicities (DLTs)
measured Up to 28 days
Permalink · PFE's whole pipeline · Catalyst calendar · Every registered study · What changed